Oyster Point Pharmaceuticals rallies $22 mln Series A
San Francisco-based Oyster Point Pharmaceuticals Inc., a developer of treatments for dry eye and other diseases of the ocular surface, has closed $22 million in Series A financing. New Enterprise Associates and Versant Ventures led the round.
8 November 2017•1 min read
